Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenABCWY antibody persistence and booster study in adolescents
2016-002230-69Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of Meningococcal ABCYW vaccine and meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease (5 arms), sponsored by GSK. Primary endpoint: Percentage of subjects with HR-hSBA titers at or above LLOQ. Started Sep 2016; status: completed.
02
Drugs
Meningococcal ABCYW vaccinemeningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2016-002230-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002230-69.